- Home
- CYCN vs QNCX Comparison
CYCN vs QNCX Comparison
Compare CYCN & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYCN | QNCX |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6M | 17.5M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CYCN | QNCX |
|---|---|---|
| Price | $23.52 | $29.48 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 114.2K | 14.1K |
| Earning Date | 05-08-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.26 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,074,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.70 | N/A |
| 52 Week Low | $1.03 | $0.08 |
| 52 Week High | $8.48 | $35.41 |
Technical Indicators
Market Signals| Indicator | CYCN | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 41.06 | 48.26 |
| Support Level | $3.04 | $0.82 |
| Resistance Level | $3.42 | $35.38 |
| Average True Range (ATR) | 0.49 | 2.14 |
| MACD | -0.03 | -0.84 |
| Stochastic Oscillator | 23.67 | 34.79 |
Price Performance
Historical ComparisonAbout CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.